{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T16:57:22Z","timestamp":1785776242862,"version":"3.56.0"},"reference-count":22,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction and Aims<\/jats:title>\n                    <jats:p>The number of patients receiving immune checkpoint inhibitor (ICI) therapy for cancer is expected to increase further; hence, heightened awareness of immune\u2010related adverse effects (irAEs) such as hypophysitis (ICI\u2010Hp) is essential. Acute ICI\u2010Hp is a common endocrine irAE of ICI therapy, and our aim was to describe its diagnostic pattern, treatment outcomes, endocrinopathies, and recovery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Records and imaging of all patients with ICI\u2010Hp (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200922), referred to a dedicated endocrine\u2010ICI clinic, were retrospectively reviewed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The median time for onset of ICI\u2010Hp was 13 weeks (IQR 9, 17), after the 3rd (IQR 3, 4) cycle of therapy. 55% of patients were female, with a median age of 67 years (IQR 53, 74), and 77% had metastatic melanoma. A combination of ipilimumab and nivolumab was used in 68% of those developing ICI\u2010Hp. Headache (64%), fatigue (77%), nausea (64%), and hyponatraemia (41%) were the most common symptoms at presentation. Secondary adrenal insufficiency (SAI) was seen in 100%, secondary hypothyroidism (SH) in 41%, and secondary hypogonadism (SHG) in 27%. An enlarged pituitary gland (64%), thickened stalk (50%), mild optic chiasm compression (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093), and asymptomatic pituitary enlargement (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091) were noted on pituitary imaging. Glucocorticoid (GC) treatment regimens included intravenous methylprednisolone (IV MPP) (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20094), prednisolone (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20098), dexamethasone (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091), and oral hydrocortisone stress dosing for 48\u2009h (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20096). Complete resolution of symptoms and significant resolution of imaging findings were noted in all, independent of regimen. Acute psychosis was noted with IV MPP (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091). None recovered SAI during follow\u2010up, whilst recovery of SH and SHG was noted in 33% and 67%, respectively. Additionally, new\u2010onset type 1 diabetes developed in 18%, with DKA in 3 patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ICI\u2010Hp is common and potentially associated with serious complications in the absence of prompt recognition and treatment. Assessment of recovery of the HP\u2010thyroid and HP\u2010gonadal axes is important; however, ACTH deficiency is more likely to be permanent, hence requiring long\u2010term GC replacement and appropriate patient education. Occurrence of ICI\u2010Hp is most commonly seen after the 3rd cycle of combination ICI therapy, and in the future it may be appropriate to warn treating physicians (and perhaps patients) of the symptoms to flag after the third cycle of combination immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/cen.70137","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T11:34:21Z","timestamp":1774438461000},"page":"331-338","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immune Checkpoint Inhibitor Therapy Induced Hypophysitis; A Tertiary Care Centre Experience; Highlighting Detection, Treatment Outcomes and Long Term Endocrinopathies and Recovery"],"prefix":"10.1111","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6309-7140","authenticated-orcid":false,"given":"Shani A. D.","family":"Mathara Diddhenipothage","sequence":"first","affiliation":[{"name":"Oxford Centre for Diabetes, Endocrinology, and Metabolism, Churchill Hospital, Oxford University Hospitals NHS trust Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqui","family":"Warden","sequence":"additional","affiliation":[{"name":"Department of Oncology Oxford University Hospitals NHS Trust Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Herbert","sequence":"additional","affiliation":[{"name":"Department of Oncology Oxford University Hospitals NHS Trust Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Pofi","sequence":"additional","affiliation":[{"name":"Oxford Centre for Diabetes, Endocrinology, and Metabolism, Churchill Hospital, Oxford University Hospitals NHS trust Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Joseph","sequence":"additional","affiliation":[{"name":"Department of Radiology Oxford University Hospitals NHS Trust, Oxford Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Coupe","sequence":"additional","affiliation":[{"name":"Department of Oncology Oxford University Hospitals NHS Trust Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miranda","family":"Payne","sequence":"additional","affiliation":[{"name":"Department of Oncology Oxford University Hospitals NHS Trust Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy W.","family":"Tomlinson","sequence":"additional","affiliation":[{"name":"Oxford Centre for Diabetes, Endocrinology, and Metabolism, Churchill Hospital, Oxford University Hospitals NHS trust Oxford UK"},{"name":"NIHR Oxford Biomedical Research Centre Oxford University Hospitals NHS trust Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen E.","family":"Turner","sequence":"additional","affiliation":[{"name":"Oxford Centre for Diabetes, Endocrinology, and Metabolism, Churchill Hospital, Oxford University Hospitals NHS trust Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/17446651.2019.1701434"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvad012"},{"key":"e_1_2_7_4_1","article-title":"The Risk of Adrenal Insufficiency After Treatment With Relatlimab in Combination With Nivolumab is Higher Than Expected","volume":"110","author":"Chamorro\u2010Pareja N.","year":"2025","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab672"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-22-0689"},{"key":"e_1_2_7_7_1","unstructured":"NHS England. NHS rolls out \u201c5 Minute Super jab\u201d for 15 Cancers 2025April 2 https:\/\/www.england.nhs.uk\/2025\/04\/nhs-rolls-out-5-minute-super-jab-for-15-cancers\/."},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac359"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1987.tb00780.x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rcl.2011.02.012"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A1836"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvac036"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16071340"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-022-01024-4"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.80988"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2025.06.008"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A6692"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-024-09902-z"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-2213"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1167975"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-0608"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-0710"},{"key":"e_1_2_7_23_1","unstructured":"National Institute for Health and Care Excellence (NICE). Adrenal Insufficiency: Identification and Management. NICE Guideline NG243.2024Aug 28."}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cen.70137","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cen.70137","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cen.70137","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T16:33:15Z","timestamp":1785774795000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cen.70137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1111\/cen.70137"],"URL":"https:\/\/doi.org\/10.1111\/cen.70137","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"2025-12-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}